Phase I/II dose-escalating trial of GEN 1 in combination with bevacizumab [Avastin] and liposomal doxorubicin [Doxil] in patients with platinum-resistant and recurrent ovarian cancer.

Trial Profile

Phase I/II dose-escalating trial of GEN 1 in combination with bevacizumab [Avastin] and liposomal doxorubicin [Doxil] in patients with platinum-resistant and recurrent ovarian cancer.

Planning
Phase of Trial: Phase I/II

Latest Information Update: 19 Apr 2016

At a glance

  • Drugs GEN 1 (Primary) ; Bevacizumab; Doxorubicin liposomal
  • Indications Ovarian cancer
  • Focus Adverse reactions
  • Sponsors Celsion Corporation
  • Most Recent Events

    • 19 Apr 2016 According to a Celsion Corporation media release, this trial is expected to begin in fourth quarter of 2016.
    • 12 Apr 2016 According to Celsion media release, this trial is expected to begin in the second half of 2016.
    • 12 Oct 2015 According to Celsion media release, company is planning to initiate this trial in mid 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top